Plasminogen Deficiency (PLGD) is an ultra-rare genetic disease that can have devastating effects on multiple organ systems throughout the body. Ligneous Conjunctivitis (LC) is a sentinel manifestation of PLGD; approximately 80% of patients with PLGD have experienced LC. PLGD has most often being diagnosed in children and is associated with the abnormal accumulation or growth of fibrin-rich pseudomembranous lesions on mucous membranes such as the conjunctiva, gums, and linings of the airways and genitourinary tract.

We learn more about this illness from Dr. Shira Robbins of the Shiley Eye Institute, University of California San Diego. Sharing her very personal journey with PLGD is a young lady (Andrea) who’s been affected by plasminogen deficiency since birth. Also joining the discussion is her mother (Jessica) who has been a formidable PLGD advocate. Prometic is a biopharmaceutical corporation with globally recognized expertise in bioseparation and uses its own affinity technology for the development of best in class plasma-derived therapeutics and orphan drugs. Prometic’s plasminogen IV has shown a great promise for the treatment of both Ligneous Conjunctivitis and PLGD, and, has received orphan and fast track designations, as well as a rare pediatric disease designation from the FDA, with anticipated BLA approval in early 2018.



Visit: [ Ссылка ]
Like: [ Ссылка ]
Follow: [ Ссылка ]

#TheBalancingAct #BalancingAct

104342

свернуть